๎๊ฒ์
๎๊ฒ์
๎
Abivax SA
ABVX๎ญ๊ด์ฌ ๋ชฉ๋ก์ ์ถ๊ฐ
102.230USD
-4.430-4.15%
์ข
๊ฐย 09-16 16:00๏ผET๏ผ
0.00์๊ฐ์ด์ก
0.00P/E TTM
์ฅ์ ๊ฑฐ๋ย 04:38ย (ET)103.490USD+1.260+1.23%
์ฅ์ ๊ฑฐ๋ย 04:38ย (ET)์์ธํ ๋ด์ฉ์ Abivax SA ํ์ฌ
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Abivax SA ํ๋กํ
๎์ข
๋ชฉ ์ฝ๋ ABVX
ํ์ฌ ์ด๋ฆAbivax SA
์์ฅ์ผJun 26, 2015
CEOde Garidel (Marc)
์ง์ ์- -
์ ํDepository Receipt
ํ๊ณ ์ฐ๋ ์ข
๋ฃ- -
์ฃผ์7-11 Boulevard Haussmann
๋์PARIS
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐFrance
์ฐํธ ๋ฒํธ75009
์ ํ33153830963
์น์ฌ์ดํธhttps://www.abivax.com/
์ข
๋ชฉ ์ฝ๋ ABVX
์์ฅ์ผJun 26, 2015
CEOde Garidel (Marc)
Abivax SA์ ํ์ฌ ์์์ง
๎์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Maurus de la Rosa, Ph.D.
Dr. Maurus de la Rosa, Ph.D.
Senior Vice President - Research
Senior Vice President - Research
--
--
Dr. Keith Fournier, Ph.D.
Dr. Keith Fournier, Ph.D.
Senior Vice President - Global Regulatory Affair
Senior Vice President - Global Regulatory Affair
--
--
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
Mr. Marc De Garidel
Mr. Marc De Garidel
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Ida Hatoum
Ms. Ida Hatoum
Chief People Officer, Chief Compliance Officer
Chief People Officer, Chief Compliance Officer
--
--
Dr. June H. Lee, M.D.
Dr. June H. Lee, M.D.
Independent Director
Independent Director
--
--
๋ ๋ณด๊ธฐ
์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Maurus de la Rosa, Ph.D.
Dr. Maurus de la Rosa, Ph.D.
Senior Vice President - Research
Senior Vice President - Research
--
--
Dr. Keith Fournier, Ph.D.
Dr. Keith Fournier, Ph.D.
Senior Vice President - Global Regulatory Affair
Senior Vice President - Global Regulatory Affair
--
--
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
์์ฃผ ๋ฌป๋ ์ง๋ฌธ
Abivax SA์ ์์ 5๋ ์ฃผ์ฃผ๋ ๋๊ตฌ์ธ๊ฐ์?
๎Abivax SA์ ์์ 5๋ ์ฃผ์ฃผ๋ ๋ค์๊ณผ ๊ฐ์ต๋๋ค: Mr. Pierre Courteille
Abivax SA(ABVX)์ ์ฃผ์์ ๋ณด์ ํ ๊ธฐ๊ด์ ๋ช ๊ฐ์ ๋๊น?
๎2026Q1 ๊ธฐ์ค์ผ๋ก, Abivax SA์ ์ฃผ์์ ๋ณด์ ํ ๊ธฐ๊ด์ ์ด 353๊ณณ์ด๋ฉฐ, ์ด๋ค์ด ๋ณด์ ํ ์ฃผ์์ ์ด ๊ฐ์น๋ ์ฝ 61.40M๋ก ์ ์ฒด ๋ฐํ ์ฃผ์์ 78.18%๋ฅผ ์ฐจ์งํฉ๋๋ค. ์ด๋ 2025Q4 ๋๋น -289711.00 ์ฆ๊ฐํ ์์น์
๋๋ค.